Chimeric antigen receptor T-cell therapies: Optimising the dose.

Area of Science:

• Immunology
• Cellular Therapy
• Oncology

Background:

• Chimeric antigen receptor (CAR) T-cells are engineered lymphocytes that target tumor antigens.
• CAR T-cell therapies are approved for B-cell malignancies, with many products in development.
• CAR T-cells display unique pharmacokinetics, including proliferation and potential long-term persistence.

Purpose of the Study:

• To explore the complex relationship between CAR T-cell dose and patient exposure.
• To identify factors influencing CAR T-cell pharmacokinetics and efficacy.
• To discuss the need for re-evaluating dosing strategies and optimizing clinical trial designs.

Main Methods:

• Review of existing literature on CAR T-cell therapy, pharmacokinetics, and dosing.
• Analysis of factors affecting CAR T-cell dose-exposure relationships.
• Discussion of traditional 3+3 dose escalation designs and alternative Phase I trial designs.

Main Results:

• CAR T-cell dose-exposure is highly variable, influenced by CAR design, patient factors, disease burden, and co-therapies.
• Current dosing is product- and indication-specific, with potential for stratification by disease burden.
• Dosing may require re-evaluation with changes in lymphodepleting regimens, indications, or manufacturing.

Conclusions:

• Optimizing CAR T-cell dosing is essential for balancing safety, efficacy, and manufacturing.
• Alternative Phase I trial designs may better identify optimal CAR T-cell doses compared to 3+3 designs.
• Continued research into CAR T-cell pharmacokinetics and dosing strategies is critical for advancing the field.